15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Surgepays Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $3.50 to $3.50, so the covering firms are broadly aligned. The average target of $3.50 sits 1776% above the current $0.19. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.02 next quarter toward $0.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Surgepays Inc.
As of Aug, 1 of 1 firms rate SURG a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SURG EPS & revenue forecast
EPS · NEXT QUARTER
$-0.02
Range $-0.02 – $-0.02 · 1 analysts · -97% YoY
Next period, 1 analysts expect Surgepays Inc to earn $-0.02 a share (range $-0.02 – $-0.02), versus $-0.69 a year earlier. Full-year consensus is $-0.70, growing to $0.05 the year after.
REVENUE · NEXT QUARTER
$16.5M
Range $16.5M – $16.5M · 1 analysts · +2% YoY
Revenue is expected to reach $16.5M (range $16.5M – $16.5M), +1.9% year-over-year. Full-year consensus is $65.0M, rising to $80.1M next year.
Top analysts covering Surgepays Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SURG.
#1
MD
Michael Diana
Maxim Group · Rank #173
Hold
No targeton SURG
Overall win rate
42%
+ Follow
#2
Edward Woo
Ascendiant Capital · Rank #419
Buy
$3.50+1775.7% to target
Overall win rate
25%
+ Follow
SURG stock forecast FAQ
What is SURG's average 12-month price target?+
The 1 analysts with a live target average $3.50 for Surgepays Inc over the next 12 months, ranging from a $3.50 high to a $3.50 low.
Is SURG stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover SURG?+
1 analysts have an active rating on Surgepays Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering SURG?+
Among analysts who currently cover SURG, Michael Diana of Maxim Group has the strongest overall Quantellect track record (Rank #173). Their current call is Hold.
What is Surgepays Inc's projected EPS for next quarter?+
The consensus estimate is $-0.02 per share (range $-0.02 – $-0.02) across 1 analysts. Full-year EPS is projected at $-0.70, rising to $0.05 the following year.
How much revenue is Surgepays Inc expected to report next quarter?+
Consensus revenue is $16.5M (range $16.5M – $16.5M). Full-year revenue is projected at $65.0M, growing to $80.1M next year.
Have analysts been upgrading or downgrading SURG lately?+
As of Aug, 1 of 1 firms rate SURG a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SURG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
